Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel
NASDAQ:RVPH

Reviva Pharmaceuticals Q1 2026 Earnings Report

Reviva Pharmaceuticals logo
$0.68 -0.08 (-10.01%)
As of 03:59 PM Eastern
ProfileEarnings HistoryForecast

Reviva Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$0.33
Beat/Miss
N/A
One Year Ago EPS
N/A

Reviva Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Reviva Pharmaceuticals Announcement Details

Quarter
Q1 2026
Date
5/21/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Reviva Pharmaceuticals' Q1 2026 Press ReleasePress Release
(8-K)
Reviva Pharmaceuticals' Q1 2026 Quarterly reportQuarterly report
(10-Q)

Reviva Pharmaceuticals Earnings Headlines

Reviva Pharmaceuticals (NASDAQ:RVPH) Rating Lowered to "Sell" at Wall Street Zen
June 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30821856
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
May 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/reviva-participate-fireside-chat-g-120000847.html
Trump’s secret China deal
Trump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, Jensen Huang, Tim Cook, and the CEOs of BlackRock, Goldman Sachs, and CitiBank. The media covered the handshakes. But what was really being negotiated behind closed doors? Porter Stansberry has connected the Beijing trip to a landmark pact signed by 13 nations in Washington - a pact designed to cut China out of a $3 trillion investment wave tied to the most critical resource of the 21st century. His new documentary exposes the five assets at the center of it all.tc pixel
June 12 at 1:00 AM  |  Porter & Company (Ad)
Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3296578/0/en/reviva-to-participate-in-fireside-chat-at-a-g-p-s-annual-healthcare-company-showcase.html
OTC Listing Leaves Reviva Pharmaceuticals Shares Vulnerable to Thin Trading and Volatile Price Swings
May 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/otc-listing-leaves-reviva-pharmaceuticals-shares-vulnerable-to-thin-trading-and-volatile-price-swings?utm_source=marketbeat.com&utm_medium=referral
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/13/3294478/0/en/reviva-reports-first-quarter-2026-financial-results-and-recent-business-highlights.html
See More Reviva Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals (NASDAQ:RVPH), Inc. (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings. Reviva maintains a lean operating model, leveraging partnerships with contract development and manufacturing organizations (CDMOs) to accelerate product development and optimize market entry.

Reviva’s current offerings span oral, injectable and topical dosage forms across therapeutic areas including metabolic disorders, dermatology and ophthalmology. In addition to its marketed portfolio, the company is advancing reformulation projects designed to improve delivery profiles, simplify dosing regimens and extend product lifecycles for previously approved drugs.

Led by Chief Executive Officer Mark C. Capparelli, Reviva’s management team combines expertise in pharmaceutical development, regulatory strategy and commercialization. The company serves markets throughout North America and works with specialty distributors in select regions to ensure broad patient access to its branded and licensed products.

View Reviva Pharmaceuticals Profile
Earnings Tools